Systematic review and meta-analysis of high-pressure intermittent limb compression for the treatment of intermittent claudication

Abstract

HPILC is associated with a significant increase in ACD compared with controls. Limb compression appears to be an effective, noninvasive treatment option for patients with intermittent claudication. However, there are few studies comparing limb compression with other commonly used therapies. Further studies are needed to better guide the use of HPILC in the treatment of claudication.

A randomized controlled trial of treatment with intermittent negative pressure for intermittent claudication

“…Between-group comparisons showed a significant difference in the change of PWD favoring the treatment group over the sham control group (estimated treatment effect 50 m, 95% CI [11,89], p= .014) (table II)…”

“…Although based on a subgroup analysis, this finding indicates that the patients with the most symptomatic disease may benefit the most from INP treatment. Multiple studies have documented the beneficial effects of SET programs on walking capacity, functional status and quality of life in patients with IC 5, 34-38 . However, a systematic review from 2016 concludes that only one third of IC patients were suitable for, or willing to undertake SET, and outlines that the adherence to SET programs are Treatment of the calf or the foot with intermittent pneumatic compression (IPC) is also suggested to improve walking distances in patients with IC 11 . Both INP and IPC increase arterial blood flow acutely when applied to the lower limb 22,33,41 , which may increase arterial shear stress, thereby inducing flow-mediated vasodilatation 22,42 .…”

“…However, the availability of SET programs is low 8 , and many patients are unwilling or unable to participate 9 . Consequently, homebased exercise programs and different treatment devices have been suggested as alternative treatment options [10][11][12] .…”

Effect of Polymer Type on the Dissolution Profile of a Solid Dispersion of Cilostazol

“…Cilostazol, a quinolinone derivative, is a selective inhibitor of type 3 phosphodiesterase (PDE3) and has antiplatelet and antithrombotic properties . Cilostazol is used for the treatment of chronic arterial occlusive disease and intermittent claudication; cilostazol was developed by Otsuka Pharmaceutical Co., Ltd., and is commercially available as immediate‐release (50 and 100 mg) or controlled‐release tablets (200 mg) for the treatment of intermittent claudication .…”

“…[1][2][3] Cilostazol is used for the treatment of chronic arterial occlusive disease and intermittent claudication; cilostazol was developed by Otsuka Pharmaceutical Co., Ltd., and is commercially available as immediate-release (50 and 100 mg) or controlled-release tablets (200 mg) for the treatment of intermittent claudication. [1][2][3] Cilostazol is used for the treatment of chronic arterial occlusive disease and intermittent claudication; cilostazol was developed by Otsuka Pharmaceutical Co., Ltd., and is commercially available as immediate-release (50 and 100 mg) or controlled-release tablets (200 mg) for the treatment of intermittent claudication.…”